Extensive alteration of fungal gene transcript accumulation and elevation of G-protein-regulated cAMP levels by a virulence-attenuating hypovirus.
Persistent infection of the chestnut blight fungus Cryphonectria parasitica with the prototypic hypovirus CHVI-713 results in attenuation of fungal virulence (hypo-virulence) and reduced accumulation of the GTP-binding (G) protein a subunit CPG-1. Transgenic cosuppression of CPG-1 accumulation in the absence of virus infection also confers hypovirulence. We now report the use of mRNA differential display to examine the extent to which virus infection alters fungal gene transcript accumulation and to assess the degree to which modification of CPG-1 signal transduction contributes to this alteration. More than 400 PCR products were identified that either increased (296 products) or decreased (127 products) in abundance as a result of virus infection. Significantly, 65% of these products exhibited similar changes as a result of CPG-1 cosuppression in the absence of virus infection. We also report that both virus infection and CPG-1 cosuppression elevate cAMP levels 3- to 5-fold. Additionally, it was possible to mimic the effect of virus infection and CPG-1 cosuppression on transcript accumulation for representative fungal genes by drug-induced elevation of cAMP levels. These results strengthen and extend previous indications that hypovirus infection causes a significant and persistent alteration of fungal gene expression/transcript accumulation. They further show that this alteration is primarily mediated through modification of the CPG-1 signaling pathway and suggest that, similar to mammalian Gi alpha subunits, CPG-1 functions as a negative modulator of adenylyl cyclase. Finally, these results suggest a role for G-protein-regulated cAMP accumulation in hypovirus-mediated alteration of fungal gene expression.
Chen
B
B
Center for Agricultural Biotechnology, University of Maryland Biotechnology Institute, College Park 20742-3351, USA.
Gao
S
S
Choi
G H
GH
Nuss
D L
DL
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D005656:Fungal Proteins / Q000096:biosynthesis*; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D019204:GTP-Binding Proteins / Q000096:biosynthesis*; D005800:Genes, Fungal; D020962:Heterotrimeric GTP-Binding Proteins; D016133:Polymerase Chain Reaction; D012328:RNA Viruses / Q000502:physiology*; D012331:RNA, Fungal / Q000096:biosynthesis; D012333:RNA, Messenger / Q000096:biosynthesis; D015398:Signal Transduction; D013806:Theophylline / Q000494:pharmacology; D014158:Transcription, Genetic; D014774:Virulence; D014779:Virus Replication; D013098:Xylariales / Q000472:pathogenicity* / Q000502:physiology / Q000821:virology*
C091426:CPG-1 protein, Cryphonectria parasitica; D005656:Fungal Proteins; D012331:RNA, Fungal; D012333:RNA, Messenger; D002110:Caffeine; D013806:Theophylline; D000242:Cyclic AMP; D019204:GTP-Binding Proteins; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D020962:Heterotrimeric GTP-Binding Proteins; D015056:1-Methyl-3-isobutylxanthine